FDG PET/CT in oncology: "raising the bar"

Clinical Radiology

Volumn 65, Issue 7, 2010, Pages 522-535

  Patel, C N ^a   Goldstone, A R ^b   Chowdhury, F U ^b   Scarsbrook, A F ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BARIUM; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IODINATED CONTRAST MEDIUM; IODINE DERIVATIVE;

ARTICLE; BREATHING PATTERN; CANCER RADIOTHERAPY; CANCER SCINTISCANNING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET RESTRICTION; DOSE CALCULATION; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; IMAGE QUALITY; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT PLANNING; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77953292410     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2010.01.003     Document Type: Article

References (112)

1. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 42 Suppl. (2001) 1S-93S
2. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22 (2004) 4357-4368
3. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 (2006) 405-422
4. Blodgett T.M., Meltzer C.C., and Townsend D.W. PET/CT: form and function. Radiology 242 (2007) 360-385
5. Poeppel T.D., Krause B.J., Heusner T.A., et al. PET/CT for staging and follow-up of patients with malignancy. Eur J Radiol 70 (2009) 382-392
6. Board of the Faculty of Clinical Radiology. PET-CT in the UK: a strategy for development and integration of a leading edge technology within routine clinical practice (2005), The Royal College of Radiologists, London
7. Committee for Indications for PET-CT. Oncology FDG PET-CT scan referral criteria (2009), PET/CT Advisory Board, London: UK
8. Hilner B.E., Siegel B.A., Liu D., et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the national oncologic PET registry. J Clin Oncol 26 (2008) 2155-2161
9. Beyer T., and Townsend D.W. Putting "clear" into nuclear medicine: a decade of PET/CT development. Eur J Nucl Med Mol Imaging 33 (2006) 857-861
10. Beyer T., Townsend D.W., Brun T., et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 41 (2000) 1369-1379
11. Hany T.F., Steinert H.C., Goerres G.W., et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225 (2002) 575-581
12. Mittra E., and Quon A. PET/CT: the current technology and applications. Radiol Clin North Am 47 (2009) 147-160
13. Kadrmas D.J., Casey M.E., Conti M., et al. Impact of time-of-flight on PET tumor detection. J Nucl Med 50 (2009) 1315-1323
14. Williams G., and Kolodny G.M. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol 190 (2008) W151-W156
15. Williams G., and Kolodny G.M. Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET. AJR Am J Roentgenol 190 (2008) 1406-1409
16. Tatsumi M., Engles J.M., Ishimori T., et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med 45 (2004) 1189-1193
17. Blodgett T. Best practices in PET/CT: consensus on performance of positron emission tomography-computed tomography. Semin Ultrasound CT MRI 29 (2008) 236-241
18. Hamberg L.M., Hunter G.J., Alpert N.M., et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification. J Nucl Med 35 (1994) 1308-1312
19. Alkhawaldeh K., Bural G., and Kumar R. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 35 (2008) 246-252
20. Zytoon A.A., Murakami K., El-Kholy M.R., et al. Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer. Clin Radiol 63 (2008) 1213-1227
21. Lodge M.A., Lucas J.D., Marsden P.K., et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 26 (1999) 22-30
22. Zhuang H., Pourdehnad M., Lambright E.S., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42 (2001) 1412-1417
23. Chen Y.M., Huang G., Sun X.G., et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun 29 (2008) 425-430
24. Anon. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources (March 2006), Administration of Radioactive Substances Advisory Committee, Oxon
25. Alessio A.M., Kinahan P.E., Manchanda V., et al. Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med 50 (2009) 1570-1577
26. Fahey F.H. Dosimetry of pediatric PET/CT. J Nucl Med 50 (2009) 1483-1491
27. Huang B., Law M.W., and Khong P. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251 (2009) 166-174
28. Brix G., Lechel U., Glatting G., et al. Radiation exposure of patients undergoing whole body dual modality 18F FDG PET/CT examinations. J Nucl Med 46 (2005) 608-613
29. McCollough C.H., Primak A.N., Braun N., et al. Strategies for reducing radiation dose in CT. Radiol Clin North Am 47 (2009) 27-40
30. Masuda Y., Kondo C., Matsuo Y., et al. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med 50 (2009) 844-848
31. Nehmeh S.A., Erdi Y.E., Ling C.C., et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med 43 (2002) 876-881
32. 18F-FDG PET/CT respiratory gating on detected metabolic activity in lung lesions. Ann Nucl Med 23 (2009) 191-196
33. Erdi Y., Nehmeh S.A., Pan T., et al. The CT motion quantification of lung lesions and its impact on PET-measured SUVs. J Nucl Med 45 (2004) 1287-1292
34. Beyer T., Antoch G., Blodgett T., et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30 (2003) 588-596
35. Osman M.M., Cohade C., Nakamoto Y., et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med 44 (2003) 240-243
36. Beyer T., Antoch G., Muller S., et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 45 (2004) 25S-35S
37. Zhao B., Yang Y., Li T., et al. Image-guided respiratory-gated lung stereotactic body radiotherapy: which target definition is optimal?. Med Phys 36 (2009) 2248-2257
38. Miles K.A. PET-CT in oncology: making the most of CT. Cancer Imaging 4 (2008) S87-S93
39. Von Schulthess G.K. Integrated modality imaging with PET-CT and SPECT-CT: CT issues. Eur Radiol 15 (2005) S121-S126
40. Antoch G., Freudenberg L.S., Beyer T., et al. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 45 (2004) 56S-65S
41. Burger C., Georres G., Schoenes S., et al. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med 29 (2002) 922-927
42. Kinahan P.E., Townsend D.W., Beyer T., et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 25 (1998) 2046-2053
43. Antoch G., Freudenberg L.S., Egelhof T., et al. Focal tracer uptake: a potential artifact in cedual-modality PET/CT scans. J Nucl Med 43 (2002) 1339-1342
44. Bunyaviroch T., Turkington T.G., Wong T.Z., et al. Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol 10 (2008) 107-113
45. Nehmeh S.A., Erdi Y.E., Kalaigian H., et al. Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT. J Nucl Med 44 (2003) 1940-1944
46. Dizendorf E., Hany T.F., Buck A., et al. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 44 (2003) 732-738
47. Antoch G., Kuehl H., Kanja J., et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid contrast-induced artefacts: introduction and evaluation. Radiology 230 (2004) 879-885
48. Groves A.M., Kayani I., Dickson J.C., et al. Oral contrast medium in PET/CT: should you or shouldn't you?. Eur J Nucl Med Mol Imaging 32 (2005) 1160-1166
49. Blodgett T., Fukui M.B., Snyderman C.H., et al. Combined PET-CT in the head and neck: part I. Physiologic, altered physiologic, and artifactual FDG uptake. RadioGraphics 25 (2005) 897-912
50. Yau Y.Y., Chan W.S., Tam Y.M., et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?. J Nucl Med 46 (2005) 283-291
51. Mawlawi O., Erasmus J.J., Munden R.F., et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol 186 (2006) 308-319
52. Badiee S., Franc B.L., Webb E.M., et al. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol 191 (2008) 1436-1439
53. Pfannenberg A.C., Aschoff P., Brechtel K., et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol 80 (2007) 437-445
54. Rodríguez-Vigil B., Gómez-León N., Pinilla I., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 (2006) 1643-1648
55. Pfannenberg A.C., Aschoff P., Brechtel K., et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34 (2007) 36-44
56. Strobel K., Heinrich S., Bhure U., et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49 (2008) 1408-1413
57. Kumar R., and Das C.J. Hybrid PET-dynamic CECT in the management of breast cancer. Eur J Nucl Med Mol Imaging 36 (2009) 413-415
58. Veit-Haibach P., Treyer V., Strobel K., et al. Feasibility of integrated CT-liver perfusion in routine FDG PET/CT. Abdom Imaging (2009) [Epub ahead of print]
59. Kuehl H., Veit P., Rosenbaum S.J., et al. Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J Nucl Med 48 Suppl. (2007) 45S-57S
60. Mah D., and Chen C.C. Image guidance in radiation oncology treatment planning: the role of imaging technologies on the planning process. Semin Nucl Med 38 (2008) 114-118
61. ICRU. Report 62, prescribing, recording and reporting photon beam therapy. (Supplement to ICRU Report 50) (1999), International commission on Radiation Units and Measurements, Washington DC
62. 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 51 (2001) 923-931
63. Riegel A.C., Berson A.M., Destian S., et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys 65 (2006) 726-732
64. Khoo V.S., and Joon D.L. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol 79 (2006) S2-S15
65. Heron D.E., Andrade R.S., Beriwal S., et al. PET-CT in radiation oncology. The impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol 31 (2008) 352-362
66. Ford E.C., Herman J., Yorke E., et al. 18F-FDG PET/CT for image-guided and intensity modulated radiotherapy. J Nucl Med 50 (2009) 1655-1665
67. Breen S.L., Publicover J., De Silva S., et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys 68 (2007) 763-770
68. Dizendorf E., Baimert B., Von Schulthess G., et al. Impact of whole-body 18F-FDG on staging and managing patients for radiation therapy. J Nucl Med 44 (2003) 24-32
69. Mageras G., and Yorke E. Deep inspiration breath-hold and respiratory gating strategies for reducing organ motion in radiation treatment. Semin Radiat Oncol 14 (2004) 65-75
70. Nehmeh S.A., Erdi Y.E., Pan T., et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 31 (2007) 3179-3186
71. Greco C., Rosenzweig K., Cascini G.L., et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57 (2007) 125-134
72. Ahn P.H., and Garg M.K. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med 38 (2008) 141-148
73. MacManus M., Nestle U., Rosenzweig K.E., et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 91 (2009) 85-94
74. Nestle U., Kemp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46 (2005) 1342-1348
75. Cannon D.M., and Lee N.Y. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for hand and neck cancer. Int J Radiat Oncol Biol Phys 70 (2008) 660-665
76. WHO. Who handbook for reporting results of cancer treatment. Offset publication No. 48 (1979), World Health Organization, Geneva
77. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
78. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer 45 (2009) 228-247
79. Zhao B., Schwartz L.H., Moskowitz C., et al. Computerized quantification of tumor response in lung cancer: initial results. Radiology 241 (2006) 892-898
80. Eisenhauer E.A. Response evaluation: beyond RECIST. Ann Oncol 18 (2007) S29-S32
81. Zhao B., Schwartz L.H., and Larson S.M. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med 50 (2009) 239-249
82. Bos R., van Der Hoeven J.J., van Der Wall E., et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
83. Wahl R.L., Zasadny K., Helvie M., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11 (1993) 2101-2111
84. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46 (2005) 983-995
85. Minn H., Paul R., and Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29 (1988) 1521-1525
86. Kasamon Y.L., and Wahl R.L. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 20 (2008) 206-219
87. Hicks R.J. The role of PET in monitoring therapy. Cancer Imaging 5 (2005) 51-57
88. Boellaard R. Standards for PET image acquisitions and quantitative data analysis. J Nucl Med 50 Suppl. 1 (2009) 11S-20S
89. Roedl J.B., Halpern E.F., Colen R.R., et al. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol 11 (2009) 54-60
90. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 35 (1999) 1773-1782
91. Shankar L.K., Hoffman J.M., Bacharach S., et al. Guidelines for the use of 18FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 47 (2006) 1059-1066
92. Juweid M.E., Wiseman G.A., Vose J.M., et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 23 (2005) 4652-4661
93. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 Suppl. 1 (2009) 122S-150S
94. Povoski S.P., Neff R.L., Mojzisik C.M., et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol 7 (2009) 11
95. Essner R., Daghighian F., and Giuliano A.E. Advances in FDG PET probe in surgical oncology. Cancer J 8 (2002) 100-108
96. Schillaci O. PET probes and oncological surgery: a productive new marriage for nuclear medicine?. Eur J Med Mol Imaging 34 (2007) 1530-1533
97. Piert M., Burian M., Meisetschlager G., et al. Positron detection for the intraoperative localisation of cancer deposits. Eur J Nuc Med Mol Imaging 34 (2007) 1534-1544
98. Gulec S.A., Hoenie E., Hostetter R., et al. PET probe-guided surgery: applications and clinical protocol. World J Surg Oncol 5 (2007) 65
99. Nwogu C., Fischer G., Tan D., et al. Radioguided detection of lymph node metastasis in non-small cell lung cancer. Ann Thorac Surg 82 (2006) 1815-1820
100. Andersen P.A., Chakera A.H., Klausen T.L., et al. Radiation exposure to surgical staff during F-18-FDG guided cancer surgery. Eur J Nucl Med Mol Imaging 35 (2008) 624-629
101. Englmeier K.H., and Seemann M.D. Multimodal virtual bronchoscopy using PET/CT images. Comp Aided Surg 13 (2008) 106-113
102. Seemann M.D., Schaefer J.F., and Englmeier K.H. Virtual positron emission tomography/computed tomography-bronchoscopy: possibilities, advantages and limitations of clinical application. Eur Radiol 17 (2007) 709-715
103. 18F-FDG PET/CT for virtual bronchoscopy and colonoscopy. J Nucl Med 47 (2006) 1081-1087
104. Antoch G., and Bockisch A. Combined PET/MRI: a dimension in whole-body oncology imaging?. Eur J Nucl Med Mol Imaging 36 Suppl. 1 (2009) S113-S120
105. Schlemmer H.P., Pichler B.J., Schmand M., et al. Simultaneous MR/PET imaging of the human brain: a feasibility study. Radiology 248 (2008) 1028-1035
106. Pichler B.J., Wehrl H.F., Kolb A., et al. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging?. Semin Nucl Med 38 (2008) 199-208
107. Delso G., and Ziegler S. PET/MRI system designs. Eur J Nucl Med Mol Imaging 36 Suppl. 1 (2009) S86-S92
108. Von Schulthess G.K., and Schlemmer H.P. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging 36 Suppl. 1 (2009) S3-S9
109. Hofmann M., Pichler B., Schölkopf B., et al. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 36 Suppl. 1 (2009) S93-104
110. Schlemmer H.P., Pichler B.J., Krieg R., et al. An integrated MR/PET system: prospective applications. Abdom Imaging 34 (2009) 668-674
111. Hicks R.J., and Lau E.W. PET/MR: a different spin from under the rim. Eur J Nucl Med Mol Imaging 36 Suppl. 1 (2009) S10-S14
112. Domingues R.C., Carneiro M.P., Lopes F.C., et al. Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol 192 (2009) 1012-1020